Extavia® (interferon beta-1b)
FDA-Approved Medications: Administered by Self-Injection
Company: Novartis Pharmaceuticals Corp.
- Administered by subcutaneous injection every other day; dose is 250 mcg
- Approved for relapsing forms of MS and for individuals with CIS
Extavia is an interferon beta-1b that is biologically identical to Betaseron and made in an identical process, but marketed by a different company. It was released in early 2010.
Extavia shares all prescribing, side effect, and safety information with Betaseron. The two pharmaceutical companies manage the patient-support programs differently; prices and copayments may also vary. The latest information is available through the patient-support programs at these two companies. For more information, visit mymsaa.org, and select “About MS,” and “Prescription Assistance Programs.”